United States-based OTITOPIC has added a new indication for treatment of lung cancer for its Aspirin inhalation product, it was reported yesterday.

The product when inhaled in Dry Powder formulation directly into the deep sites of the lung is a novel new approach to lung cancer treatment. The company says that treatment can potentially provide benefits superior to other common therapies, greatly improving clinical results for patients being treated for lung cancer.

The product has been demonstrated to have extensive pharmacological activities including anti-inflammation, anticancer and pain-relieving activities. It also inhibits platelets and has blood thinning properties which are beneficial in preventing and treating heart attacks.